YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models

scientific article

YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1039494278
P356DOI10.1038/SREP06031
P932PMC publication ID4129416
P698PubMed publication ID25112436
P5875ResearchGate publication ID264745868

P2093author name stringJun Zeng
Li Liu
Yong Xia
Qian Lei
Yuquan Wei
Shuang Zhang
Xuejiao Song
Guobo Li
Hongjun Lin
Luoting Yu
Nana Meng
Youzhi Xu
Tinghong Ye
Yongxia Zhu
Yinglan Zhao
Deliang Li
Senyi Deng
Youli Pan
P2860cites workHallmarks of Cancer: The Next GenerationQ22252312
Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptorQ24311900
Targeting HIF-1 for cancer therapyQ27860504
Tumor angiogenesis: therapeutic implicationsQ27860595
Stages of embryonic development of the zebrafishQ27860947
High frequency of mutations of the PIK3CA gene in human cancersQ28131776
Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cellsQ28248642
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerQ28251373
Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathwayQ28385231
Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesisQ28535457
The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer modelQ28538542
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismQ29547302
The STATs of cancer--new molecular targets come of ageQ29614601
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisQ29617585
Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafishQ33308472
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro studyQ33495790
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3Q33780701
Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathwayQ33787400
Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.Q52507969
Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferationQ73441800
A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cellsQ73677814
Transplacental carcinogenesis by stilbestrolQ95784569
Targeting mTOR signaling for cancer therapyQ34220084
Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.Q34355711
An overview of small-molecule inhibitors of VEGFR signalingQ34611616
Role of Akt signaling in vascular homeostasis and angiogenesisQ34712853
Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesisQ34729610
EdU, a new thymidine analogue for labelling proliferating cells in the nervous systemQ34876083
VEGF and the quest for tumour angiogenesis factorsQ34932327
Angiogenesis assays: a critical overviewQ35036728
Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activationQ35622038
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogsQ35640098
Targeting Stat3 in cancer therapyQ36147972
Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancerQ36178164
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyQ36278239
Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E.Q36489757
Hypoxia-inducible factors: central regulators of the tumor phenotypeQ36701590
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.Q37435425
The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.Q37832021
Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodiesQ38312556
Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer.Q39421427
SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivoQ39521060
SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivoQ39534138
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activityQ40023447
Inhibition of cell proliferation and in vitro markers of angiogenesis by indole-3-carbinol, a major indole metabolite present in cruciferous vegetablesQ40406706
STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cellsQ40416582
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impactQ43077944
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.Q44106085
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Q44285254
Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin geneQ45857630
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectangiogenesis inhibitorQ574834
P304page(s)6031
P577publication date2014-08-12
P1433published inScientific ReportsQ2261792
P1476titleYLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models
P478volume4

Reverse relations

cites work (P2860)
Q91863172Alkaloid extract of Corydalis yanhusuo inhibits angiogenesis via targeting vascular endothelial growth factor receptor signaling
Q38757723Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility
Q90400032Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest and Apoptosis
Q38286128Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy
Q33614936Disruption of Angiogenesis by Anthocyanin-Rich Extracts of Hibiscus sabdariffa
Q36772187Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.
Q45755977Integrated in silico and experimental methods revealed that Arctigenin inhibited angiogenesis and HCT116 cell migration and invasion through regulating the H1F4A and Wnt/β-catenin pathway.
Q86552947Niclosamide inhibits the inflammatory and angiogenic activation of human umbilical vein endothelial cells
Q36528249Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
Q35274726Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model
Q64072900Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases
Q35983858Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis
Q64987622The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Q37520154The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer
Q38558371The promise of zebrafish as a chemical screening tool in cancer therapy
Q47898529Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.
Q38833891Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges
Q40715107Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches
Q47586776miR-1273g-3p participates in acute glucose fluctuation-induced autophagy, dysfunction, and proliferation attenuation in human umbilical vein endothelial cells

Search more.